Clinical trials
Psilocybin clinical trials
Below are recruiting psilocybin clinical trials, each written for real people, not researchers. We’re tracking 100 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06796361RecruitingPhase 1
Psilocybin's effect on consciousness: serotonin receptor role
This study tests how psilocybin (the active ingredient in magic mushrooms) affects consciousness by blocking a specific serotonin receptor in the brain. It helps researchers understand why psilocybin causes altered states of mind.
Basel, Canton of Basel-CityAges 25–75 - NCT07347405RecruitingPhase 1
Psilocybin Whole Mushroom for OCD Treatment
This trial tests a whole-mushroom version of psilocybin as a potential treatment for OCD that hasn't improved with standard therapies. Participants receive psilocybin in a controlled setting and are monitored closely for safety and changes in symptoms.
Tucson, ArizonaAges 18 years+ - NCT07638553RecruitingPhase 3
Psilocybin to prevent alcohol relapse with depression
This study tests whether psilocybin (a psychedelic compound) can help people with severe alcohol use disorder stay sober longer, especially if they also have depression. Participants receive guided psilocybin sessions alongside counseling to reduce the risk of returning to heavy drinking.
BayonneAges 18 years+ - NCT06692192RecruitingPhase 1
Midazolam and psilocybin for wellbeing study
This trial tests how two different drugs, midazolam and psilocybin, affect the brain and wellbeing. It may help if you feel your wellbeing has dropped a bit but you don't have a diagnosed mood or anxiety disorder.
Madison, WisconsinAges 18–65 - NCT07180108Enrolling by invitationPhase 1
Psilocybin and music study for healthy volunteers
This study tests how music affects your experience with psilocybin, a psychedelic substance. It may help researchers understand how to create the best setting for psilocybin therapy.
Baltimore, MarylandAges 21–75 - NCT07211438RecruitingPhase 2
Psilocybin with Monitors for Treatment-Resistant Depression
This study tests whether trained monitors improve the safety and outcomes of psilocybin therapy for people with depression that hasn't responded to other treatments. Participants will receive psilocybin in a supervised setting and will need to temporarily stop other psychiatric medications.
Toronto, OntarioAges 18–70 - NCT06132178RecruitingPhase 2
Psilocybin and rTMS for hard-to-treat depression
This study tests whether a combination of psilocybin (a psychedelic substance) and transcranial magnetic stimulation (rTMS, a noninvasive brain stimulation) can help people with treatment-resistant depression. It involves daily visits to the research center for about 2 weeks.
Austin, TexasAges 22–65 - NCT06160232RecruitingPhase 2
Psilocybin therapy for severe alcohol use disorder
This trial tests whether psilocybin, a psychedelic substance, combined with talk therapy can help people with severe alcohol use disorder stop or reduce drinking. Participants will first complete a 4-week inpatient detox program before receiving psilocybin in a supervised setting.
BrusselsAges 21–64 - NCT06200155RecruitingPhase 2
Psilocybin therapy for advanced cancer patients with anxiety or depression
This trial tests whether a drug called psilocybin, given with therapy, can help people with advanced cancer who are feeling anxious or depressed. You must have a stable cancer and be willing to travel to Houston for treatment.
Houston, TexasAges 25 years+ - NCT06319378RecruitingPhase 2
Psilocybin for cancer-related depression
This trial tests whether a single dose of psilocybin, a psychedelic medication, can safely and effectively treat major depression in people with cancer. If you have cancer and have been feeling depressed for at least a month, you may qualify.
Gothenburg, GöteborgAges 20–80 - NCT06592833RecruitingPhase 2
Psilocybin with or without pimavanserin for depression
This study tests whether combining psilocybin (a psychedelic substance) with pimavanserin (a medication that may help reduce side effects) works better than psilocybin alone for treating major depressive disorder. It may help people who have not responded well to other treatments.
New York, New YorkAges 21–80 - NCT06768944RecruitingPhase 2
Psilocybin and Subjective Experience Study
This study looks at how psilocybin affects people's subjective experience. It aims to understand the mind-altering effects of this psychedelic compound in healthy volunteers.
Calgary, AlbertaAges 18–65 - NCT06810310RecruitingPhase 2
Psilocybin for motivation in opioid use disorder
This study tests whether a single dose of psilocybin (the active ingredient in magic mushrooms) can help people with opioid use disorder stay motivated in recovery. It uses brain scans to see how psilocybin affects brain areas linked to motivation.
Philadelphia, PennsylvaniaAges 18–60 - NCT06888128RecruitingPhase 2
Psilocybin for PTSD in veterans
This study tests whether a guided psilocybin session can help veterans heal from trauma-related PTSD. If you're a veteran with PTSD, you may be able to join.
Houston, TexasAges 21–64 - NCT07104916RecruitingPhase 2
Mindfulness and psilocybin therapy for PTSD
This study tests whether a combination of mindfulness training and a single dose of psilocybin can help reduce PTSD symptoms. It is for people with moderate-to-severe PTSD who are not on certain medications and do not have major health problems.
Columbus, OhioAges 21–65 - NCT07169747RecruitingPhase 2
Psilocybin with therapy for young adults with anorexia
This study tests two different doses of psilocybin, a substance that may help change thinking patterns, given alongside psychological support to young adults with anorexia nervosa. It aims to see if it is safe and helpful for weight recovery and mental health.
LundAges 16–35 - NCT07226232RecruitingPhase 3
Psilocybin for veterans with treatment-resistant depression
This study tests whether psilocybin (a psychedelic substance) can help veterans with depression that hasn't improved with standard treatments.
Birmingham, AlabamaAges 18–75 - NCT07565493RecruitingEarly Phase 1
Psilocybin with a serotonin blocker in healthy adults
This early-stage research study tests how psilocybin (a naturally occurring compound from certain mushrooms) works when combined with a medication that blocks a specific serotonin pathway in the brain. Researchers want to understand how these two substances interact in healthy volunteers to inform future psychiatric treatment studies.
Baltimore, MarylandAges 21–60 - NCT06899165RecruitingPhase 2
Psilocybin therapy for inherited trauma
This trial tests whether psilocybin (a psychedelic substance) combined with therapy can help adult children of genocide survivors who experience symptoms of trauma, depression, or anxiety. The goal is to see if this approach can reduce the emotional impact of intergenerational trauma.
New York, New YorkAges 18 years+ - NCT06969170RecruitingPhase 2
Psilocybin oral solution for generalized anxiety disorder trial
This study tests a psilocybin oral solution in adults with generalized anxiety disorder (GAD). It aims to see if the drug is safe, tolerable, and helpful for reducing anxiety symptoms.
Kingston, OntarioAges 18–60 - NCT06349083RecruitingPhase 2
Psilocybin-assisted treatment for alcohol use disorder
This study tests whether psilocybin, a psychedelic drug, combined with therapy can help people reduce or stop drinking. It aims to understand how psilocybin affects the brain and behavior in people with alcohol use disorder.
New York, New YorkAges 18–65 - NCT06656702RecruitingEarly Phase 1
Psilocybin for depression in amyotrophic lateral sclerosis
This trial tests whether psilocybin, a psychedelic drug, can safely help with depression in people with ALS. It also looks at how the drug affects your symptoms and quality of life over six months.
Baltimore, MarylandAges 18 years+ - NCT07251491RecruitingPhase 1/Phase 2
Psilocybin for depression after spinal cord injury
This trial tests whether psilocybin (a substance found in certain mushrooms) can help treat depression in people with a spinal cord injury. You would receive the study drug in a controlled setting, and your progress would be monitored closely.
The Bronx, New YorkAges 22 years+ - NCT06233344RecruitingPhase 2
Mindfulness and psilocybin study for healthy adults
This study tests whether combining mindfulness training with a single dose of psilocybin (a psychedelic found in certain mushrooms) can help healthy adults. It aims to explore how these two approaches together might improve well-being.
Los Angeles, CaliforniaAges 25 years+
Hear when a new Psilocybin trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for psilocybin?
- Yes. Clin2 currently lists 100 recruiting psilocybin studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a psilocybin trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a psilocybin trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.